Regeneron Pharmaceuticals, Inc. (Regeneron) is a biopharmaceutical company. Regeneron discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. As of December 31, 2010, the Company had one marketed product: ARCALYST (rilonacept) injection for subcutaneous use, which is available for prescription in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older. Its late stage programs are VEGF Trap-Eye (aflibercept ophthalmic solution), which is being developed for the prevention and treatment of serious eye diseases; ARCALYST, which is being developed for the prevention of gout flares in patients initiating uric acid-lowering treatment, and aflibercept (VEGF Trap), which is being developed in oncology in collaboration with the sanofi-aventis Group.
Faizan's take
REGN closed at $65.2 a share on Friday. This stock has a lot of momentum on its side, and can make a decent up move in the next couple of months.
Price target $74 (12.8% gain).
NOTE: Suggested price targets are very flexible and may change as the price action unfolds. Targets are only suggested to give readers a rough estimate of what to expect from the stock and they should not be used by investors as absolute sell points.
